liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Regulatory Peptides as Disease Markers
Linköping University, Faculty of Health Sciences. Linköping University, Department of Biomedicine and Surgery, Division of clinical chemistry. Östergötlands Läns Landsting, Centre for Laboratory Medicine, Department of Clinical Chemistry.
2004 (English)In: Journal of The International Federation of Clinical Chemistry And Laboratory Medicine, ISSN 1051-2292, Vol. 15, no 3Article in journal (Other academic) Published
Abstract [en]

Measurement of regulatory peptides has an established role in the diagnosis and monitoring of heart failure, severe infections and of several peptide-producing tumours, including endocrine pancreatic tumours, carcinoid tumours, medullary thyroid carcinomas; pheochromocytomas and neuroblastomas. Proper sample handling (rapid cooling and freezing) is important since most regulatory peptides (except brain natriuretic peptides (BNP, N-BNP), procalcitonin, gastrin and pancreatic polypeptide) are labile in plasma. High assay specificity is generally an advantage but when diagnosing peptide-producing tumours the immunoassay used should preferably have broad specificity for the peptide family to be analysed since endocrine tumours may result in elevated concentrations of different spectra of the peptides in individual patients. Peptide- producing endocrine tumours co-secrete chromogranin A together with their respective characteristic hormones/regulatory peptides. Chromogranin A is therefore the most valuable general marker for neuroendocrine tumours. Analyses of several regulatory peptides during diagnosis and follow-up in patients in endocrine oncology units are well established. However, very few studies have as yet addressed the specificity and predictive value of analyses of regulatory peptides. The predictive value of any laboratory test is dependent not only on quality of test and the reference limits used, but also on the prevalence of disease in the population under study. In the case of endocrine tumours the prevalence of the disease in the population is extremely low, and results from analyses of regulatory peptides in patients not known to have peptide producing tumours should be interpreted with utmost care so that further unnecessary investigations are avoided.

Place, publisher, year, edition, pages
2004. Vol. 15, no 3
Keyword [en]
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-23630Local ID: 3122OAI: diva2:243945
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2011-01-12

Open Access in DiVA

No full text

Other links

Search in DiVA

By author/editor
Theodorsson, Elvar
By organisation
Faculty of Health SciencesDivision of clinical chemistryDepartment of Clinical Chemistry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 9 hits
ReferencesLink to record
Permanent link

Direct link